The presentations will highlight the safety and efficacy benefits of Prolong’s lead asset, PP-007, including in “Blood Is Not An Option” (BNAO) patients in acute injury/treatment settings
SOUTH PLAINFIELD, N.J.--(BUSINESS WIRE)--Prolong Pharmaceuticals, LLC (the Company), a clinical-stage biopharmaceutical company, announced that the Company will deliver two oral presentations, an oral abstract, and two posters at the International Symposium on Blood Substitutes (ISBS) held on November 14-18, 2024, in National Harbor, Maryland.
Oral Presentations
Presenter: | Dr. Shaunak Pandya, Director, CMC R&D, Prolong Pharmaceuticals | |
Session: | Updates on Bio-Synthetic Blood Components | |
Title: | PEGylated Bovine Hemoglobin: Manufacturing and Characterization | |
Date/Time: | Friday, November 15, 2024, 7:30 PM–7:55 PM ET | |
Presenter: | Dr. Ronald Jubin, Vice President of R&D, Prolong Pharmaceuticals | |
Session: | Bio-Synthetic Blood Components in Active Human Trials | |
Title: | SANGUINATE® Clinical Trials | |
Date/Time: | Sunday, November 17, 2024, 2:35 PM–3:00 PM ET | |
*Date/Times subject to change | ||
The Company will present its lead asset, PP-007 (PEGylated carboxyhemoglobin bovine, also known as SANGUINATE®), a novel clinical stage biopharmaceutical product that is universally compatible, thermally stable, and in a ready-to-administer intravenous formulation. PP-007 recently received Fast Track Designation in acute ischemic stroke and the Company is actively planning a pivotal approval trial.
Hemorrhagic shock is considered the leading cause of death in trauma patients leading to 30-40% of deaths. Given ~50% of these deaths occur in the pre-hospital period due to blood loss, there is an urgent need for versatile treatments for a broad range of patients where blood transfusion is not an option (BNAO) or when blood is not readily available. BNAO patients treated in PP-007’s safety studies demonstrated survival benefits, warranting further investigation.
“PP-007 has tremendous potential in improving blood flow and increasing survival in patients suffering from hemorrhagic/hypovolemic shock, ischemia/hypoxia, and severe anemia. Its diverse applications—including rapidly transferring oxygen, improving perfusion and organ function, and reducing inflammation—make it relevant across a breadth of indications, such as trauma, ischemic stroke, oncology, and more. Whether as a monotherapy or adjunct treatment, we are encouraged by the collective data supporting PP-007’s numerous mechanisms of action,” says Ronald Jubin, Ph.D. Vice President of R&D at Prolong Pharmaceuticals.
In addition to numerous published non-clinical studies of ischemia/hypoxia and anemia, over 300 individuals in 12 completed clinical trials have received single or multi-dose PP-007 treatments including subarachnoid hemorrhage, life-threatening anemia, and other diseases/conditions with an underlying ischemia/hypoxia component, such as beta thalassemia and sickle cell disease. PP-007 is an investigational drug product and not approved for use in any country/indication.
About Prolong Pharmaceuticals, LLC
Prolong Pharmaceuticals is an advanced clinical stage pharmaceutical company that is vertically integrated with a proprietary state-of-the-art manufacturing facility headquartered in South Plainfield, New Jersey. Prolong Pharmaceuticals is developing PP-007 as a treatment for acute ischemic stroke to lessen the debilitating comorbidities associated with reduced quality of life, increased medical cost, and significant mortality.
Contacts
Ronald Jubin, Ph.D.
Vice President, Early Development
Prolong Pharmaceuticals
(908) 315-5762
rjubin@prolongpharma.com
